The Next Big Thing In Biotech: Onyx
Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg why Onyx Pharmaceuticals is the next big thing in biotech.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
